<DOC>
	<DOCNO>NCT01601366</DOCNO>
	<brief_summary>Adenomyosis disease entity diagnose endometrial gland stroma deep myometrium associate surround myometrial hypertrophy . The finding classically associate adenomyosis excessive uterine bleeding accompany worsen dysmenorrhea . The advent endovaginal US substantially improve ability diagnose adenomyosis . Different US feature adenomyosis report , include uterine enlargement explainable presence leiomyoma , asymmetric thicken anterior posterior myometrial wall , lack contour abnormality mass effect , heterogeneous poorly circumscribe area within myometrium , anechoic lacuna cyst vary size , increased echotexture myometrium . Transvaginal power Doppler application useful study vascular tree adenomyosis aid clinician plan appropriate therapeutic strategy . The differential diagnosis use power Doppler sonography base vascular characteristic . Adenomyosis characterize preserve vascular texture supply result dilate spiral artery run perpendicular toward myometrium endometrial surface . Leiomyomata exhibit vascular tree typically circumscribe solid mass . 2D transvaginal power Doppler angiography use improve diagnostic sensitivity facilitate appropriate therapeutic intervention . The levonorgestrel-releasing intrauterine system ( IUS ) , Mirena , approve Europe contraception since 1990 . Because suppressive effect levonorgestrel endometrium , Mirena also proven effective management menorrhagia dysmenorrhea , progestin component postmenopausal hormone therapy . It introduce Taiwan 1995 alternative therapy idiopathic menorrhagia . Many case menorrhagia cause adenomyosis , Mirena , therefore , introduce treatment adenomyosis Taiwan . The current study design evaluate best treatment modality treatment adenomyosis clinical assessment dysmenorrhea chronic pelvic pain visual analogue scale menstrual blood loss menstrual diary , image ultrasound Doppler index .</brief_summary>
	<brief_title>LNG-IUS Treatment Dysmenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Adenomyosis</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>1 . Women dysmenorrhoea and/or chronic pelvic pain secondary adenomyosis . 2 . Planning birth space least 2 year . 3 . Patient age 2045 year old . 4 . Ultrasonographic Doppler examination suggestive adenomyosis . 5 . Living nearby area make followup reasonably possible . 1 . Pregnancy 2 . Evidence defective coagulation . 3 . History evidence malignancy . 4 . Hyperplasia endometrial biopsy . 5 . Incidental adnexal abnormality ultrasound . 6 . Contraindications COCs . 7 . Absolute contraindication LNGIUS insertion . 8 . Previous endometrial ablation resection 9 . Uninvestigated postcoital bleeding 10 . Untreated abnormal cervical cytology</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Adenomyosis</keyword>
	<keyword>Intrauterine levonorgestrel</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Oral contraceptive</keyword>
	<keyword>Uterus</keyword>
</DOC>